CY1125198T1 - Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς - Google Patents

Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς

Info

Publication number
CY1125198T1
CY1125198T1 CY20221100352T CY221100352T CY1125198T1 CY 1125198 T1 CY1125198 T1 CY 1125198T1 CY 20221100352 T CY20221100352 T CY 20221100352T CY 221100352 T CY221100352 T CY 221100352T CY 1125198 T1 CY1125198 T1 CY 1125198T1
Authority
CY
Cyprus
Prior art keywords
compounds
treatment
isochromanyl
analogues
heterocyclic
Prior art date
Application number
CY20221100352T
Other languages
Greek (el)
English (en)
Inventor
Linghong Xie
Philip Glyn JONES
Kerry L. Spear
Noel Aaron Powell
Taleen G. Hanania
Vadim ALEXANDROV
Original Assignee
Pgi Drug Discovery Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pgi Drug Discovery Llc filed Critical Pgi Drug Discovery Llc
Publication of CY1125198T1 publication Critical patent/CY1125198T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20221100352T 2015-02-11 2022-05-20 Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς CY1125198T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11

Publications (1)

Publication Number Publication Date
CY1125198T1 true CY1125198T1 (el) 2024-12-13

Family

ID=55456908

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100352T CY1125198T1 (el) 2015-02-11 2022-05-20 Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς

Country Status (22)

Country Link
US (4) US9856238B2 (https=)
EP (2) EP4046995B1 (https=)
JP (3) JP6657241B2 (https=)
KR (1) KR102601972B1 (https=)
CN (2) CN111925360B (https=)
AU (1) AU2016219253C1 (https=)
CA (1) CA2976095C (https=)
CY (1) CY1125198T1 (https=)
DK (1) DK3256466T3 (https=)
EA (1) EA201791804A1 (https=)
ES (2) ES2911910T3 (https=)
HU (1) HUE058698T2 (https=)
IL (1) IL253914B (https=)
MX (2) MX371404B (https=)
MY (1) MY188160A (https=)
NZ (1) NZ735011A (https=)
PH (1) PH12017501422A1 (https=)
PL (1) PL3256466T3 (https=)
PT (1) PT3256466T (https=)
SG (2) SG11201706515QA (https=)
UA (1) UA122222C2 (https=)
WO (1) WO2016130796A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111171047B (zh) * 2015-02-11 2023-06-23 赛诺维信制药公司 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物
PL3256466T3 (pl) * 2015-02-11 2022-05-23 Sunovion Pharmaceuticals Inc. Związki 1-heterocykliloizochromanylu i analogi do leczenia zaburzeń oun
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
CN121221782A (zh) 2017-06-30 2025-12-30 傲拓神经科学公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
JP2002519348A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー 5−ht1fアゴニスト
SE9902267D0 (sv) 1999-06-16 1999-06-16 Astra Ab New compounds
CA2465186A1 (en) * 2001-11-08 2003-05-15 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
EP1831203A1 (en) * 2004-12-21 2007-09-12 F. Hoffmann-Roche AG Chroman derivatives and uses thereof in the treatment of cns disorders
CN101203505A (zh) 2005-04-22 2008-06-18 惠氏公司 苯并二氢吡喃和苯并吡喃衍生物及其用途
AU2007209382A1 (en) * 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of CNS disorders
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
CN106883246B (zh) 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
AR090557A1 (es) 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
EP2938341B1 (en) 2012-12-31 2018-09-05 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
PL3256466T3 (pl) * 2015-02-11 2022-05-23 Sunovion Pharmaceuticals Inc. Związki 1-heterocykliloizochromanylu i analogi do leczenia zaburzeń oun

Also Published As

Publication number Publication date
NZ735011A (en) 2023-07-28
UA122222C2 (uk) 2020-10-12
AU2016219253A1 (en) 2017-09-21
EA201791804A1 (ru) 2018-02-28
WO2016130796A1 (en) 2016-08-18
MX2017010363A (es) 2018-05-04
EP4046995C0 (en) 2023-09-13
CN111925360A (zh) 2020-11-13
IL253914B (en) 2021-09-30
ES2911910T3 (es) 2022-05-23
US9856238B2 (en) 2018-01-02
MX2020001157A (es) 2022-05-27
JP2018505205A (ja) 2018-02-22
HUE058698T2 (hu) 2022-09-28
EP4046995A1 (en) 2022-08-24
PL3256466T3 (pl) 2022-05-23
US20180093974A1 (en) 2018-04-05
EP3256466A1 (en) 2017-12-20
CN107531674B (zh) 2020-07-31
JP7023994B2 (ja) 2022-02-22
KR20170129730A (ko) 2017-11-27
IL253914A0 (en) 2017-10-31
AU2016219253C1 (en) 2022-12-08
PH12017501422A1 (en) 2018-03-19
MX392664B (es) 2025-03-24
CN111925360B (zh) 2024-03-22
US11192885B2 (en) 2021-12-07
SG10201806809QA (en) 2018-09-27
EP3256466B1 (en) 2022-04-06
MY188160A (en) 2021-11-24
US20190389845A1 (en) 2019-12-26
EP4046995B1 (en) 2023-09-13
PT3256466T (pt) 2022-05-10
ES2967643T3 (es) 2024-05-03
JP2020079282A (ja) 2020-05-28
SG11201706515QA (en) 2017-09-28
US20220185799A1 (en) 2022-06-16
MX371404B (es) 2020-01-29
CN107531674A (zh) 2018-01-02
ES2911910T9 (es) 2022-08-12
EP3256466B9 (en) 2022-07-27
AU2016219253B2 (en) 2020-10-01
KR102601972B1 (ko) 2023-11-13
US20170001987A1 (en) 2017-01-05
BR112017017354A2 (pt) 2018-04-10
CA2976095C (en) 2023-10-17
DK3256466T3 (da) 2022-05-02
JP6657241B2 (ja) 2020-03-04
CA2976095A1 (en) 2016-08-18
JP2022065050A (ja) 2022-04-26
US10336732B2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
CY1125198T1 (el) Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1125230T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1124542T1 (el) Ενωση πυριμιδινης
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1123443T1 (el) Οξεα καρβαμοϋλοξυμεθυλ-τριαζολ-κυκλοεξυλιου ως ανταγωνιστες lpa
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CY1124631T1 (el) 11-υποκατεστημενες 24-υδροξυστερολες για χρηση στην αγωγη nmda σχετιζομενων παθησεων
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
JOP20190125B1 (ar) مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
MX2016011992A (es) Derivados de piperidina-diona.
MX376106B (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b.
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
CY1126082T1 (el) Τροποποιητες toy trex1
EP4484440A3 (en) Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CY1121746T1 (el) Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MX388175B (es) Compuestos terapéuticos y métodos para utilizarlos